King Wealth Management Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

King Wealth Management Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,000	Closed	-$353K	–	173
2021 Q4	$353K	Sell	4,000 -1,000	-20%	-$82.5K	0.07%	125
2021 Q3	$386K	Hold	5,000	–	–	0.08%	114
2021 Q2	$417K	Hold	5,000	–	–	0.09%	110
2021 Q1	$378K	Buy	+5,000	New	+$408K	0.08%	114

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

King Wealth Management Group's BMRN Position: Q1 2022 in Review

King Wealth Management Group sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2022, closing a stake of 4,000 shares — an estimated $353K sold.

King Wealth Management Group first reported a position in BMRN in Q1 2021 and held it in 4 quarters. The position peaked at $417K in Q2 2021. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.

King Wealth Management Group reported no remaining BioMarin Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
King Wealth Management Group sold 4,000 BioMarin Pharmaceuticals shares in Q1 2022, an estimated $353K.
King Wealth Management Group first reported a position in BioMarin Pharmaceuticals in Q1 2021 and held it in 4 quarters.
King Wealth Management Group's BioMarin Pharmaceuticals position peaked at $417K in Q2 2021.
560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.

Based on King Wealth Management Group's 13F filing for Q1 2022, filed 12 May 2022.